Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Lung Neoplasms: HELP
Articles by Marc Riquet
Based on 90 articles published since 2009
(Why 90 articles?)
||||

Between 2009 and 2019, M. Riquet wrote the following 90 articles about Lung Neoplasms.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4
1 Editorial [Normal and diseased lymphatics of lungs and pleura]. 2013

Riquet, M / Bernaudin, J-F. · ·Rev Pneumol Clin · Pubmed #23523229.

ABSTRACT: -- No abstract --

2 Editorial [Lung surgery for non-tumoral disease]. 2012

Riquet, M / Mordant, P. · ·Rev Pneumol Clin · Pubmed #22425503.

ABSTRACT: -- No abstract --

3 Editorial Editorial comment Sleeve lobectomy: time for setting the record straight. 2011

Riquet, Marc / Arame, Alex. · ·Eur J Cardiothorac Surg · Pubmed #21515068.

ABSTRACT: -- No abstract --

4 Review [Consequences of tobacco smoking on lung cancer treatments]. 2016

Rivera, C / Rivera, S / Fabre, E / Pricopi, C / Le Pimpec-Barthes, F / Riquet, M. ·Service de chirurgie thoracique et transplantation pulmonaire, université Paris Descartes, hôpital européen Georges-Pompidou, 20-40, rue Leblanc, 75015 Paris, France. · Service de radiothérapie, institut Gustave-Roussy, 94800 Villejuif, France. · Service d'oncologie médicale, université Paris-Descartes, hôpital européen Georges-Pompidou, 75015 Paris, France. · Service de chirurgie thoracique et transplantation pulmonaire, université Paris Descartes, hôpital européen Georges-Pompidou, 20-40, rue Leblanc, 75015 Paris, France. Electronic address: marc.riquet@egp.aphp.fr. ·Rev Pneumol Clin · Pubmed #25727658.

ABSTRACT: In France, in 2010, tobacco induced 81% of deaths by lung cancer corresponding to about 28,000 deaths. Continued smoking after diagnosis has a significant impact on treatment. In patients with lung cancer, the benefits of smoking cessation are present at any stage of disease. For early stages, smoking cessation decreases postoperative morbidity, reduces the risk of second cancer and improves survival. Previous to surgery, smoking cessation of at least six to eight weeks or as soon as possible is recommended in order to reduce the risk of infectious complications. Tobacco could alter the metabolism of certain chemotherapies and targeted therapies, such as tyrosine kinase inhibitors of the EGF receptor, through an interaction with P450 cytochrome. Toxicity of radiations could be lower in patients with lung cancer who did not quit smoking before treatment. For patients treated by radio-chemotherapy, overall survival seems to be better in former smokers but no difference is observed in terms of recurrence-free survival. For advanced stages, smoking cessation enhances patients' quality of life. Smoking cessation should be considered as full part of lung cancer treatment whatever the stage of disease.

5 Review [Obesity and lung cancer: incidence and repercussions on epidemiology, pathology and treatments]. 2015

Rivera, C / Pecuchet, N / Wermert, D / Pricopi, C / Le Pimpec-Barthes, F / Riquet, M / Fabre, E. ·Service de chirurgie thoracique, université Paris Descartes, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France. · Unité d'oncologie thoracique, université Paris Descartes, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France. · Service de pneumologie, université Paris Descartes, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France. · Service de chirurgie thoracique, université Paris Descartes, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France. Electronic address: marc.riquet@egp.aphp.fr. ·Rev Pneumol Clin · Pubmed #25681316.

ABSTRACT: INTRODUCTION: Obesity and lung cancer are major public health problems. The purpose of this work is to review the data concerning this association. METHOD: We report clinical and epidemiological data on obesity and discuss the impact on the incidence of lung cancer, as well as the safety and efficiency of anti-tumor treatments. RESULTS: Obesity does not contribute to the occurrence of lung cancer, unlike other malignancies. Patients may be more likely to undergo treatment at lower risk. Regarding surgery, obesity makes anaesthesia more difficult, increases the operative duration but does not increase postoperative morbidity and mortality. Chemotherapy and radiotherapy seem to be administered according to the same criteria as patients with normal weight. Paradoxically, survival rates of lung cancer are better in obese patients as well after surgery than after non-surgical treatment. CONCLUSION: Obesity is related to many neoplasms but not to lung cancer. Regarding long-term survival all treatments combined, it has a favorable effect: this is the "obesity paradox".

6 Review [Major pulmonary resections for lung cancer and thoracoscopic approach: some reflections on published data]. 2014

Dujon, A / Mordant, P / Saab, M / Riquet, M. ·Centre médico-chirurgical du Cèdre, Bois-Guillaume, France. · Service de chirurgie thoracique, hôpital Georges-Pompidou, 20-40 rue Leblanc, 75015 Paris, France. · Service de chirurgie thoracique, hôpital Georges-Pompidou, 20-40 rue Leblanc, 75015 Paris, France. Electronic address: marc.riquet@egp.aphp.fr. ·Rev Pneumol Clin · Pubmed #25131371.

ABSTRACT: Video-assisted thoracic surgery has a renewed topicality in treating early stage non-small cell lung cancer. Numerous publications show the benefits of this surgical technique in comparison with conventional thoracotomy. However, some surgeons are still apprehensive for its validity in lung cancer. Few works were dedicated to the critical aspect of this new technique which generates silent controversy and is far from having the general approval of all surgical teams. A critical review of several papers disclosed some concerns related to this approach, notably the risk of intra-operative technical problems and the possibility of questionable results concerning cancer dissection and clearance. A randomized clinical trial is now mandatory to confirm the safety and usefulness of this technique.

7 Review An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. 2014

Ashworth, Allison B / Senan, Suresh / Palma, David A / Riquet, Marc / Ahn, Yong Chan / Ricardi, Umberto / Congedo, Maria T / Gomez, Daniel R / Wright, Gavin M / Melloni, Giulio / Milano, Michael T / Sole, Claudio V / De Pas, Tommaso M / Carter, Dennis L / Warner, Andrew J / Rodrigues, George B. ·Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada. · Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands. · Department of Thoracic Surgery, Georges Pompidou European Hospital, Paris, France. · Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. · Department of Oncology, University of Turin, Turin, Italy. · Department of General Thoracic Surgery, Catholic University of Sacred Heart, Rome, Italy. · Division of Radiation Oncology, M.D. Anderson Cancer Center, Houston, TX. · University of Melbourne Department of Surgery, St Vincent's Hospital, Melbourne, Australia. · Department of Thoracic Surgery, San Raffaele Scientific Institute, Milan, Italy. · Department of Radiation Oncology, University of Rochester, Rochester, NY. · Department of Radiation Oncology, Instituto Madrileño de Oncología, Madrid, Spain. · Thoracic Oncology Division, European Institute of Oncology, Milan, Italy. · Department of Radiation Oncology, Rocky Mountain Cancer Centers, Aurora, CO. · Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada. Electronic address: george.rodrigues@lhsc.on.ca. ·Clin Lung Cancer · Pubmed #24894943.

ABSTRACT: INTRODUCTION/BACKGROUND: An individual patient data metaanalysis was performed to determine clinical outcomes, and to propose a risk stratification system, related to the comprehensive treatment of patients with oligometastatic NSCLC. MATERIALS AND METHODS: After a systematic review of the literature, data were obtained on 757 NSCLC patients with 1 to 5 synchronous or metachronous metastases treated with surgical metastectomy, stereotactic radiotherapy/radiosurgery, or radical external-beam radiotherapy, and curative treatment of the primary lung cancer, from hospitals worldwide. Factors predictive of overall survival (OS) and progression-free survival were evaluated using Cox regression. Risk groups were defined using recursive partitioning analysis (RPA). Analyses were conducted on training and validating sets (two-thirds and one-third of patients, respectively). RESULTS: Median OS was 26 months, 1-year OS 70.2%, and 5-year OS 29.4%. Surgery was the most commonly used treatment for the primary tumor (635 patients [83.9%]) and metastases (339 patients [62.3%]). Factors predictive of OS were: synchronous versus metachronous metastases (P < .001), N-stage (P = .002), and adenocarcinoma histology (P = .036); the model remained predictive in the validation set (c-statistic = 0.682). In RPA, 3 risk groups were identified: low-risk, metachronous metastases (5-year OS, 47.8%); intermediate risk, synchronous metastases and N0 disease (5-year OS, 36.2%); and high risk, synchronous metastases and N1/N2 disease (5-year OS, 13.8%). CONCLUSION: Significant OS differences were observed in oligometastatic patients stratified according to type of metastatic presentation, and N status. Long-term survival is common in selected patients with metachronous oligometastases. We propose this risk classification scheme be used in guiding selection of patients for clinical trials of ablative treatment.

8 Review [Lung cancer in the elderly: what about surgery?]. 2014

Rivera, C / Gisselbrecht, M / Pricopi, C / Fabre, E / Mordant, P / Badia, A / Le Pimpec-Barthes, F / Riquet, M. ·Service de chirurgie thoracique, université Paris 5, hôpital européen Georges-Pompidou, AP-HP, 20-40, rue Leblanc, 75015 Paris, France. · Service de gériatrie, université Paris 5, hôpital européen Georges-Pompidou, AP-HP, 20, rue Leblanc, 75015 Paris, France. · Service d'oncologie médicale, université Paris 5, hôpital européen Georges-Pompidou, AP-HP, 20, rue Leblanc, 75015 Paris, France. · Service de chirurgie thoracique, université Paris 5, hôpital européen Georges-Pompidou, AP-HP, 20-40, rue Leblanc, 75015 Paris, France. Electronic address: marc.riquet@egp.aphp.fr. ·Rev Pneumol Clin · Pubmed #24581796.

ABSTRACT: Geriatric oncology is a rapidly expanding domain because of the deep epidemiological changes of the last decades related to the ageing of the population. Lung cancer treatment in patients 75 years and over is a major issue of thoracic oncology. Curative surgery remains the treatment offering the best survival rates to the patient whatever his age. The important variability observed within the elderly forces us to take into account their specificities, in particular for ageing physiology and associated comorbidities. Thus, preoperative workup permitting to assess the resectability of the tumor but also the operability of the patient is all the more essential in the advanced age that it must be adapted to the particular characteristics of the elderly. Thanks to recent data of the literature, morbidity and mortality associated to surgical treatment are now better characterized and considered as acceptable in accordance with long-term survival. Clinical investigation remains essential to acquire a better knowledge of potential benefit of multimodal treatments in the elderly, for which very few data are available.

9 Review [Lymphatic extension and lymphangiogenesis in non-small cell lung cancer]. 2014

Cazes, A / Gibault, L / Rivera, C / Mordant, P / Riquet, M. ·Service d'anatomie pathologique, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Unversité Paris Descartes, 12, rue de l'École-de-Médecine, 75006 Paris, France. · Service d'anatomie pathologique, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France. · Service de chirurgie thoracique, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Unversité Paris Descartes, 12, rue de l'École-de-Médecine, 75006 Paris, France. · Service de chirurgie thoracique, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Unversité Paris Descartes, 12, rue de l'École-de-Médecine, 75006 Paris, France. Electronic address: marc.riquet@egp.aphp.fr. ·Rev Pneumol Clin · Pubmed #24566036.

ABSTRACT: Lymph node metastasis is a major adverse prognostic factor of malignant tumors, including non-small cell lung carcinoma (NSCLC). However the characterization of tumor associated lymphatic vessels and lymphangiogenic mediators in NSCLC are recent and their prognostic role is debated. Lymphatic vascular invasion (LVI) appears like a robust adverse prognostic factor when reported in NSCLC. This parameter should be better standardized and could be of use in adjuvant therapy indications. Moreover, anti-lymphangiogenesis therapies are currently under investigation and may become part of the anti-cancer strategy.

10 Review [Lymphatic spread of lung cancer: anatomical lymph node chains unchained in zones]. 2014

Riquet, M / Rivera, C / Gibault, L / Pricopi, C / Mordant, P / Badia, A / Arame, A / Le Pimpec Barthes, F. ·Service de chirurgie thoracique, laboratoire d'anatomie pathologique, hôpital européen Georges-Pompidou, université Paris-Descartes, 20-40, rue Leblanc, 75015 Paris, France. Electronic address: marc.riquet@egp.aphp.fr. · Service de chirurgie thoracique, laboratoire d'anatomie pathologique, hôpital européen Georges-Pompidou, université Paris-Descartes, 20-40, rue Leblanc, 75015 Paris, France. ·Rev Pneumol Clin · Pubmed #24566031.

ABSTRACT: Lung cancer is characterized by its lymphophilia. Its metastatic spread mainly occurs by tumor cells lymphatic drainage into the blood circulation. Initially, the lymph node TNM classification was based on clinical and therapeutic considerations, particularly concerning N2 involvement. The goals were to avoid futile exploratory thoracotomies without lung resection, to provide more accurate data from mediastinoscopy, and to take into account the radiation therapy fields. Since 1997, the international lymph node classification was more used to analyse the disparities within N1 and N2 groups. However, this attempt did not succeed in clarifying the lymphatic metastazing process, and was not progressing any more. Anatomy not being considered, it did not permit to grasp the anatomical and physiological significances of N2 and N3 involvement. In effect, this classification is now confined in zones and is lacking the anatomical and physiological descriptions that characterise the lymphatic pathways draining the lungs and their tumoral pathology. The stations proposed in numbers in cartographies should have gained in accuracy and in prognostic value if they had been expressed in their anatomical counterparts.

11 Review [Typical pulmonary carcinoid tumor: evolution, related prognostic factors and lymphadenectomy indications]. 2014

Bagan, P / Das-Neves-Pereira, J C / Rivera, C / Gibault, L / Badia, A / Mordant, P / Riquet, M / Le Pimpec Barthes, F. ·Service de chirurgie thoracique, hôpital européen Georges-Pompidou, hôpitaux universitaires Paris Ouest, université Paris 5, AP-HP, 20-40, rue Leblanc, 75015 Paris, France. · Département de chirurgie thoracique, université de Sao Paulo, 342, rue Teodore, Sao Paulo, Brésil. · Service de chirurgie thoracique, hôpital européen Georges-Pompidou, hôpitaux universitaires Paris Ouest, université Paris 5, AP-HP, 20-40, rue Leblanc, 75015 Paris, France; Département de chirurgie thoracique, université de Sao Paulo, 342, rue Teodore, Sao Paulo, Brésil. · Service de chirurgie thoracique, hôpital européen Georges-Pompidou, hôpitaux universitaires Paris Ouest, université Paris 5, AP-HP, 20-40, rue Leblanc, 75015 Paris, France. Electronic address: marc.riquet@egp.aphp.fr. ·Rev Pneumol Clin · Pubmed #24566028.

ABSTRACT: The bronchopulmonary typical carcinoid tumors are often considered as non-metastatic neoplasia. The appearance of metastases is observed in 10% of the cases. We detail here studies based on the identification of the risk factors of metastases occurrence to adapt the lung surgery and lymph node dissection to the individual patient risk.

12 Review [Lung cancer, how to deal with critical situations?]. 2014

Scotté, F / Leroy, P / Hans, S / Hervé, C / Aubaret, C / Pelicier, N / Vulser, C / Siméone, V / Nariana, E / Le Pimpec-Barthes, F / Riquet, M / Fabre, E / Oudard, S. ·Oncologie médicale, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Unité fonctionnelle de soins de support oncologiques, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Département d'éthique médicale, faculté de médecine, université Paris Descartes, 75006 Paris, France. Electronic address: florian.scotte@egp.aphp.fr. · Unité fonctionnelle de soins de support oncologiques, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Département d'éthique médicale, faculté de médecine, université Paris Descartes, 75006 Paris, France. · Service d'ORL, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France. · Département d'éthique médicale, faculté de médecine, université Paris Descartes, 75006 Paris, France. · Unité fonctionnelle de soins de support oncologiques, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Service d'ORL, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France. · Unité fonctionnelle de soins de support oncologiques, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Service de psychologie et psychiatrie de liaison, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France. · Unité fonctionnelle de soins de support oncologiques, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Unité d'évaluation et de lutte contre la douleur, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France. · Unité fonctionnelle de soins de support oncologiques, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Unité de diététique, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France. · Service de chirurgie thoracique, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France. · Oncologie médicale, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France. ·Rev Pneumol Clin · Pubmed #24560988.

ABSTRACT: The management of a patient with cancer, including lung cancer requires the investment of many health caregivers. The development of surgical techniques as well as targeted therapies requires a specialization of each. In order to optimize the actions of each, coordination of support is required from the diagnosis of cancer. This coordination can reduce iatrogenic toxicity and improve quality of life during the disease. It may also enhance quality of accompaniment of the patient, his family and a fortiori the health care team. The development of this coordination of supportive care in oncology, as part of a department of cancerology including care of patients with lung cancer is described. This organization allows to limit the toxicities of cancer treatment, but also to improve the suffering of patients by focusing on maintaining the patient at home.

13 Review A review of 250 ten-year survivors after pneumonectomy for non-small-cell lung cancer. 2014

Riquet, Marc / Mordant, Pierre / Pricopi, Ciprian / Legras, Antoine / Foucault, Christophe / Dujon, Antoine / Arame, Alex / Le Pimpec-Barthes, Françoise. ·Department of General Thoracic Surgery, Georges Pompidou European Hospital, Descartes University, Paris, France. ·Eur J Cardiothorac Surg · Pubmed #24132299.

ABSTRACT: OBJECTIVES: During the last decades, pneumonectomy has been increasingly seen as a risky procedure, first reserved for tumours not amenable to lobectomy, and now discouraged even in advanced stages of non-small-cell lung cancer (NSCLC). Our purpose was to assess the long-term survival following pneumonectomy for NSCLC and its prognostic factors. METHODS: We set a retrospective study including every patient who underwent a pneumonectomy for NSCLC in 2 French centres from 1981 to 2002. We then described the demographic and pathological characteristics of patients who survived >10 years, and studied the prognostic factors of long-term survival. RESULTS: During the study period, 1466 pneumonectomies were performed for NSCLC, including 1121 standard and 345 extended, and accounted for the overall population. Postoperative complications occurred in 396 patients (27%), including 93 deaths (6.3%). Five- and 10-year survival rates were 32 and 19%, respectively. Two-hundred and fifty patients survived >10 years after surgery, and accounted for the study group. The study group included a majority of males (n = 230, 92%), a mean age of 57 ± 9.2 years and a majority of clinical stage IIIA (n = 117, 46.8%). Induction, right-sided pneumonectomy, extended resection and adjuvant therapy were performed in 41 (16.4%), 109 (43.6%), 40 (16%) and 97 patients (38.8%), respectively. Histology revealed a majority of squamous cell carcinoma (n = 181, 72.4%), T2 tumours (n = 117, 36.8%) and N1 disease (n = 105, 42%). In multivariate analysis, factors associated with adverse outcomes included older age, advanced stage, extended resection, non-lethal postoperative complication, adenocarcinoma, lymphatic vessel microinvasion, N1 and N2 disease and R1 and R2 resection. CONCLUSIONS: During the last 30 years, pneumonectomy was effectively performed for advanced NSCLC, allowing a 10-year survival rate of 19%. Such results have not been reported with other non-surgical treatments and confirm that pneumonectomy is still an essential weapon in the armamentarium against lung cancer.

14 Review Current readings: the most influential and recent studies regarding resection of lung cancer in m1a disease. 2013

Mordant, Pierre / Rivera, Caroline / Legras, Antoine / Le Pimpec Barthes, Françoise / Riquet, Marc. ·Department of General Thoracic Surgery, Georges Pompidou European Hospital, Descartes University, Paris, France. · Department of General Thoracic Surgery, Georges Pompidou European Hospital, Descartes University, Paris, France. Electronic address: marc.riquet@egp.aphp.fr. ·Semin Thorac Cardiovasc Surg · Pubmed #24331148.

ABSTRACT: M1A disease is a recent concept appearing in the 7th TNM classification of lung cancer. M1A encompasses two different entities, malignant pleural or pericardial effusions and separate tumor nodules in the contralateral lung, who constitute very different diseases, with very different management and prognoses. On one hand, patients with pleural dissemination have extremely poor survival, with median and 5-year survivals of 4 months and 3.1%, respectively. Only selected patients whose limited pleural extension has been diagnosed at the time of thoracotomy and completely resected, may experience prolonged survival. On the other hand, recent progress in molecular biology still failed to establish whether a contralateral lesion is a second primary or a metastasis. These contralateral lesions are now gathered as multiple lung cancers in the surgical literature, and misleadingly classified as M1A disease in the TNM classification. Patients with contralateral nodules may experience prolonged survival after the surgical treatment of both localizations. Changing the staging by establishing the diagnosis of metastasis is probably an important issue warranting further biologic research, but according to current results this diagnosis must not in any case preclude surgery.

15 Review [Lymphangioma and lymphangiectasia]. 2013

Legras, A / Mordant, P / Le Pimpec-Barthes, F / Riquet, M. ·Service de chirurgie thoracique, université Paris 5, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 20, rue Leblanc, 75015 Paris, France. ·Rev Pneumol Clin · Pubmed #23688723.

ABSTRACT: Primary thoracic lymphatic diseases are both infrequent and probably under diagnosed. The two major forms are lymphangiomas and lymphangiectasias. Lymphangiomas are focal proliferation of well-differentiated lymphatic vessels. Childhood lymphangiomas may follow embryologic disorders. Adult lymphangiomas are more likely secondary to lymphatic obstruction. When associated with typical CT and MRI features, their surgical resection is not mandatory, whereas in case of diagnostic difficulties or related complications, surgical resection is the rule. Lymphangiectasias are congenital or acquired pathologic lymphatic dilatation from pleura and interlobular septa without any proliferation. These diseases can be limited to one pulmonary lobe, or can involve the whole lymphatic network. In case of communication between the lymphangiectasias and the thoracic duct, symptoms may include chyloptysis, chylothorax, and chylopericardium. Lymphangio MRI allows visualisation of the lymphangiectasis and thoracic duct. Surgical treatment may be required in case of resistance to medical treatment.

16 Review Should all cases of lung cancer be presented at Tumor Board Conferences? 2013

Riquet, Marc / Mordant, Pierre / Henni, Mehdi / Wermert, Delphine / Fabre-Guillevin, Elizabeth / Cazes, Aurélie / Le Pimpec Barthes, Françoise. ·Department of General Thoracic Surgery, Georges Pompidou European Hospital, Paris-Descartes University, 20 rue Leblanc, Paris 75015, France. marc.riquet@egp.aphp.fr ·Thorac Surg Clin · Pubmed #23566964.

ABSTRACT: Tumor Board Conferences (TBCs) have been associated with higher adherence of staging and treatment to guidelines. The influence of TBCs on the rate of curative treatments has been established. Patients with lung nodules and tumors of unknown histology should not be presented before surgery, but every patient with malignant histology should be declared to the TBC coordinator and registered at the time of histologic confirmation. This approach allows physicians to deal rapidly with simple cases on a systematic basis, to give more attention to the most complicated situations, and to offer every patient the benefit of a multidisciplinary approach.

17 Review [Anatomy, micro-anatomy and physiology of the lymphatics of the lungs and chest wall]. 2013

Riquet, M / Mordant, P / Pricopi, C / Achour, K / Le Pimpec Barthes, F. ·Service de Chirurgie Thoracique, Hôpital Européen Georges-Pompidou, 20-40, rue Leblanc, 75015 Paris, France. marc.riquet@egp.aphp.fr ·Rev Pneumol Clin · Pubmed #23523433.

ABSTRACT: The thoracic lymphatic vessels are pulsating channels which drain actively the fluid of lung parenchyma interstitium and pleural cavities. Their unidirectional valves that avoid reflux of contents, direct the current of fluid to the connection of thoracic duct to subclavian vein or to the thoracic duct itself by these pulsations. The ascending parietal and visceral currents have anastomoses between them. The parietal currents (internal thoracic anteriorly, external axillaries in lateral and paravertebral in posterior) drain the lymph of thoracic wall. Pleural cavities and the visceral currents, drain that of lungs and mediastinal organs. The thoracic duct goes upward in the posterior mediastinum and usually connects to the venous confluent of the left subclavian vein. It receives a part of thoracic lymph and also drains the lymph of trunk and inferior limbs. About a half or two thirds of thoracic duct lymph is originated from liver and intestines. The intestines have the lymph of digestion with the fatty elements, i.e., the chyle.

18 Review Prognostic factors for survival after complete resections of synchronous lung cancers in multiple lobes: pooled analysis based on individual patient data. 2013

Tanvetyanon, T / Finley, D J / Fabian, T / Riquet, M / Voltolini, L / Kocaturk, C / Fulp, W J / Cerfolio, R J / Park, B J / Robinson, L A. ·Department of Thoracic Oncology, H. Lee Moffitt Cancer Center, Tampa,FL 33612, USA. ·Ann Oncol · Pubmed #23136230.

ABSTRACT: BACKGROUND: Some reports suggest that patients with synchronous multiple foci of nonsmall-cell lung cancers (NSCLC) distributed in multiple lobes have a poor prognosis, even when there is no extrathoracic metastasis. The vast majority of such patients do not receive surgical treatment. For those who undergo surgery, prognostic factors are unclear. PATIENTS AND METHODS: We systematically reviewed the literature on surgery for synchronous NSCLC in multiple lobes published between 1990 and 2011. Individual patient data were used to obtain adjusted hazard ratios (HRs) in each dataset and pooled analyses were carried out. RESULTS: Six studies contributed 467 eligible patients for analysis. The median overall survival was 52.0 months [95% confidence interval 45.6-63.7]. Male gender and advanced age were associated with a decreased survival: HRs 1.64 (1.22, 2.22) and 1.40 (1.20, 1.80) per 20-year increment, respectively. Patients with cancers distributed in one lung had a higher mortality risk than those with bilateral disease: HRs 1.45 (1.06, 2.00). N1 or N2 had a decreased survival compared with N0: HRs 1.68 (1.12, 2.51) and 1.94 (1.33, 2.82), respectively. There was a trend toward increased mortality among patients with different histology: HRs 1.29 (0.96, 1.75). CONCLUSION: Advanced age, male gender, nodal involvement, and unilateral tumor location were poor prognostic factors.

19 Review Surgery for metastatic pleural extension of non-small-cell lung cancer. 2011

Mordant, Pierre / Arame, Alex / Foucault, Christophe / Dujon, Antoine / Le Pimpec Barthes, Françoise / Riquet, Marc. ·Service de Chirurgie Thoracique, Hôpital Européen Georges Pompidou, APHP, Paris, France. ·Eur J Cardiothorac Surg · Pubmed #21515066.

ABSTRACT: OBJECTIVE: Malignant cells in the pleural fluid or pleural metastases are now classified stage IV in lung cancer and alter the treatment. Our purpose was to question the role of surgery in such patients. METHODS: The clinical records of 4668 patients, who underwent lung cancer surgery, were reviewed. In some, an undiagnosed pleural malignant disease (M1a) was discovered during thoracotomy. When feasible, selected patients underwent complete surgical resection of the primary tumor and pleural nodules. We analyzed the epidemiology, pathology, and prognosis characteristics of that group (study group), as compared with the population undergoing pulmonary resection in a curative attempt (overall population) or exploratory thoracotomy in case of unexpected disseminated carcinomatous pleuritis (control group). RESULTS: The study group included 32 patients (25 males), mean age 59 ± 8.8 years, who underwent pneumonectomy (n = 9) or lobectomy (n = 23), associated with mediastinal lymph nodes dissection and surgical resection of associated pleural nodules. There were 21 adenocarcinomas, seven squamous cell carcinomas, two undifferentiated large cell carcinomas, and two miscellaneous tumors. Pathological node (pN) was: N0 in 10 patients (31.3%), N1 in four (12.5%), and N2 in 18 (56.3%). Five-year survival rate was 16% after resection, and 21% if the resection was a lobectomy. CONCLUSION: Complete surgical resection of non-small-cell lung cancer (NSCLC) associated with limited metastatic pleural involvement is associated with long-term survival in 16% of the cases. A review of the published data, together with the results of this series, may justify the inclusion of surgery in multimodality treatment of NSCLC patients with metastatic pleural extension.

20 Review Non-small cell lung cancer invading the chest wall. 2010

Riquet, Marc / Arame, Alex / Le Pimpec Barthes, Françoise. ·Department of Thoracic Surgery, Georges Pompidou European Hospital, 20 rue Leblanc, 75015, Paris, France. marc.riquet@egp.aphp.fr ·Thorac Surg Clin · Pubmed #20974435.

ABSTRACT: Non-Small cell lung cancer invading the chest wall represents an advanced stage of the disease. Chest wall resection may be achieved in up to 100% of the patients, and the ensuing defect requires to be reconstructed in 40% to 64% of cases. Once a surgical challenge, chest wall resection is no longer a technical problem and en bloc chest wall and lung resections regularly provide good results. However, survival rates are jeopardized by incompleteness of the resection and mediastinal lymph node involvement. Nowadays, the challenge is represented by the use of the other nonsurgical modalities (chemotherapy and radiation therapy) to increase the chance of performing a complete resection, the need to achieve a better control of probable lymphatic or hematogenous spread, and the reduction of the recurrence rate.

21 Review Prognostic classifications of lymph node involvement in lung cancer and current International Association for the Study of Lung Cancer descriptive classification in zones. 2010

Riquet, Marc / Arame, Alex / Foucault, Christophe / Le Pimpec Barthes, Françoise. ·Department of Thoracic Surgery, Georges Pompidou European Hospital, 20 rue Leblanc, 75015 Paris, France. marc.riquet@egp.aphp.fr ·Interact Cardiovasc Thorac Surg · Pubmed #20573650.

ABSTRACT: The lymphatic drainage of solid organ tumors crosses through the lymph nodes (LNs) whose tumoral involvement may still be considered as local disease. Concerning lung cancer, LN involvement may be intrapulmonary (N1), and mediastinal and/or extra-thoracic. More than 30 years ago, mediastinal involved LNs were all considered as N2, and outside the scope of surgery. In 1978, Naruke presented an original article entitled 'Lymph node mapping and curability at various levels of metastasis in resected lung cancer', demonstrating that N2 was not a contraindication to surgery in all patients. The map permitted to localize the favorable N2 on the lung cancer ipsilateral side of the mediastinum. Several maps ensued aiming to discriminate between right and left involvement (1983), and to distinguish N2 (ipsilateral) and N3 (contralateral) mediastinal LN involvement (1983, 1986). The last map (1997 regional LN classification) was recently replaced by a descriptive classification in anatomical zones. This new LN map of the TNM classification for lung cancer is a step toward using anatomical view points which might be the best way to better understand lung cancer lymphatic spread. Nowadays, the LNs are easily identified by current radiological imaging, and their resectability may be anticipated. Each LN chain may be removed by en-bloc lymphadenectomy performed during radical lung resection, a safe procedure which seems to be more oncological based than sampling, and which avoids the source of discrepancies pointed out during the labeling of LN stations by surgeons.

22 Article Surgical resection of pulmonary inflammatory pseudotumors: long-term outcome. 2017

Peretti, Marine / Radu, Dana M / Pfeuty, Karel / Dujon, Antoine / Riquet, Marc / Martinod, Emmanuel. ·1 Department of Thoracic and Vascular Surgery, Assistance Publique Hôpitaux de Paris, Avicenne Hospital, SMBH Faculty of Medicine, Paris 13 University, COMUE Sorbonne Paris Cité, Bobigny, France. · 2 Department of Thoracic and Vascular Surgery, Saint-Brieuc Hospital, France. · 3 Department of Thoracic and Vascular Surgery, Cedar Surgical Center, Bois Guillaume, France. · 4 Department of Thoracic Surgery, Assistance Publique Hôpitaux de Paris, Georges Pompidou European Hospital, Paris Descartes University, COMUE Sorbonne Paris Cité, Paris, France. ·Asian Cardiovasc Thorac Ann · Pubmed #28605954.

ABSTRACT: Background Pulmonary inflammatory pseudotumors are rare lesions that remain problematic in several aspects, especially regarding the therapeutic strategy. The goal of this study was to evaluate long-term survival in a multicenter series of patients who required surgery for pulmonary inflammatory pseudotumors. Methods Thirty-six cases of pulmonary inflammatory pseudotumors, operated on in 3 French thoracic surgery departments between 1989 and 2015, were studied retrospectively. We recorded pre-, peri- and postoperative data for each patient, and long-term survival was analyzed. Results There were 22 men and 14 women. Mean age was 53.5 years (range 14-81 years). Three pneumonectomies, 1 bilobectomy, 19 lobectomies, 2 segmentectomies, 10 wedge resections, and 1 biopsy were performed. Complete resection was carried out in 32 (88.8%) patients. Median follow-up was 76 months. Five-year and 10-year survival rates were respectively 86.8% and 81.7% (96% and 90% for patients with R0 resection). Conclusions Long-term survival was excellent for patients with pulmonary inflammatory pseudotumors who benefited from surgery, especially when surgical resection was complete. These results confirm that surgical resection must be proposed as the first-line treatment for patients with pulmonary inflammatory pseudotumors.

23 Article Induction of resident memory T cells enhances the efficacy of cancer vaccine. 2017

Nizard, Mevyn / Roussel, Hélène / Diniz, Mariana O / Karaki, Soumaya / Tran, Thi / Voron, Thibault / Dransart, Estelle / Sandoval, Federico / Riquet, Marc / Rance, Bastien / Marcheteau, Elie / Fabre, Elizabeth / Mandavit, Marion / Terme, Magali / Blanc, Charlotte / Escudie, Jean-Baptiste / Gibault, Laure / Barthes, Françoise Le Pimpec / Granier, Clemence / Ferreira, Luis C S / Badoual, Cecile / Johannes, Ludger / Tartour, Eric. ·INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, 56 Rue Leblanc, Paris 75015, France. · Equipe Labellisée Ligue Contre le Cancer, Paris 75015, France. · Department of Pathology, Hopital Européen Georges Pompidou, 20 Rue Leblanc, Paris 75015, France. · Institute of Biomedical Sciences, University of Sao Paulo, Av Prof Lineu Prestes, Sao Paulo SP-CEP 05508-900, Brazil. · Institut Curie, PSL Research University, Chemical Biology of Membranes and Therapeutic Delivery Unit, INSERM U 1143, CNRS UMR3666, 26 Rue d'Ulm 75248, Paris Cedex 05, France. · Hopital Europeen Georges Pompidou, Chrirurgie Thoracique Générale, Oncologique et Transplantation, 20 Rue Leblanc, Paris 75015, France. · Department of Medical Bioinformatics, Hopital Européen Georges Pompidou, 20 Rue Leblanc, Paris 75015, France. · Departement of Medical Oncology, Hopital Européen Georges Pompidou, 20 Rue Leblanc, Paris 75015, France. ·Nat Commun · Pubmed #28537262.

ABSTRACT: Tissue-resident memory T cells (Trm) represent a new subset of long-lived memory T cells that remain in tissue and do not recirculate. Although they are considered as early immune effectors in infectious diseases, their role in cancer immunosurveillance remains unknown. In a preclinical model of head and neck cancer, we show that intranasal vaccination with a mucosal vector, the B subunit of Shiga toxin, induces local Trm and inhibits tumour growth. As Trm do not recirculate, we demonstrate their crucial role in the efficacy of cancer vaccine with parabiosis experiments. Blockade of TFGβ decreases the induction of Trm after mucosal vaccine immunization, resulting in the lower efficacy of cancer vaccine. In order to extrapolate this role of Trm in humans, we show that the number of Trm correlates with a better overall survival in lung cancer in multivariate analysis. The induction of Trm may represent a new surrogate biomarker for the efficacy of cancer vaccine. This study also argues for the development of vaccine strategies designed to elicit them.

24 Article Medical and Economic Evaluation of FOREseal Bioabsorbable Reinforcement Sleeves Compared With Current Standard of Care for Reducing Air Leakage Duration After Lung Resection for Malignancy: A Randomized Trial. 2017

Alifano, Marco / Jayle, Christophe / Bertin, François / Magdeleinat, Pierre / Castier, Yves / Tiffet, Olivier / Bernard, Alain / Tronc, François / Brichon, Pierre-Yves / Dumont, Pascal / Grosdidier, Gilles / Dujon, Antoine / Grine, Abel / Pereira, Helena / Le Jeannic, Anais / Vinet, Marie Amélie / MaOulida, Hassani / Durand-Zaleski, Isabelle / Riquet, Marc / Chatellier, Gilles / Regnard, Jean-François / Anonymous4400891. ·*Department of Thoracic Surgery, Paris Center University Hospital, Paris Descartes University, Paris, France †Department of Thoracic Surgery, Poitiers University Hospital, Poitiers, France ‡Department of Thoracic Surgery, Limoges University Hospital, Limoges, France §Department of Thoracic Surgery, Institute Mutualiste Montsouris, Paris, France ||Department of Thoracic Surgery, Bichat University Hospital, Paris Diderot University, Paris, France ¶Department of Thoracic Surgery, St Etienne University Hospital, St Etienne, France #Department of Thoracic Surgery, Dijon University Hospital, Dijon, France **Department of Thoracic Surgery, Lyon University Hospital, Bron, France ††Department of Thoracic Surgery, Grenoble University Hospital, Grenoble, France ‡‡Department of Thoracic Surgery, Tours University Hospital, Tours, France §§Department of Thoracic Surgery, Nancy University Hospital, Nancy, France ||||Department of Thoracic Surgery, Clinique du Cedre, Rouen, France ¶¶Department of Biostatistics, Paris West University Hospital, Paris, France ##Department of Public Health and Medical Economy, Paris Center University Hospital, Paris, France ***Department of Thoracic Surgery, Paris West University Hospitals, AP-HP, Paris Descartes University, Paris, France. ·Ann Surg · Pubmed #28009728.

ABSTRACT: OBJECTIVE: The objective of this study was to determine the efficacy of alginate staple-line reinforcement of fissure openings as compared with stapling alone, with or without tissue sealant or glue, in reducing the incidence and duration of air leakage after pulmonary lobectomy for malignancy. SUMMARY BACKGROUND DATA: No randomized trial evaluating alginate staple-line reinforcement has been performed to date. METHODS: The Staple-line Reinforcement for Prevention of Pulmonary Air Leakage study was a multicenter randomized trial, with blinded evaluation of endpoints. Patients over 18 years of age scheduled for elective open lobectomy or bilobectomy for malignancy were eligible for enrollment. At thoracotomy, patients were deemed ineligible if an unanticipated pneumonectomy was indicated, or if air leakage occurred after the liberation of pleural adhesions. Otherwise, if the fissure was incomplete or the lung had an emphysematous appearance, patients were randomized to either standard management or interventional procedure consisting of fissure opening with linear cutting staplers buttressed with paired alginate sleeves (FOREseal). The number of eligible patients necessary in each randomization arm was estimated to be 190, and an outcomes analysis was performed on an intention-to-treat basis. RESULTS: Of the 611 patients consented to study enrollment, 380 met the inclusion criteria and were randomized. Based on an intention-to-treat analysis, the primary endpoint of air leak duration was not different between the 2 groups: 1 day (range: 0-2 d) in the FOREseal group and 1 day (range: 0-3 d) in the control group (P = 0.8357). In addition, the 2 groups were similar in terms of the proportion of patients presenting with prolonged air leakage (7.8% in the FOREseal group vs 11.3% in the control group, P = 0.264) and the average duration of chest drainage (P = 0.107). Procedure costs were comparable for both groups. CONCLUSIONS: FOREseal did not demonstrate a significant advantage over standard treatment alone.

25 Article Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer. 2017

Pécuchet, Nicolas / Laurent-Puig, Pierre / Mansuet-Lupo, Audrey / Legras, Antoine / Alifano, Marco / Pallier, Karine / Didelot, Audrey / Gibault, Laure / Danel, Claire / Just, Pierre-Alexandre / Riquet, Marc / Le Pimpec-Barthes, Françoise / Damotte, Diane / Fabre, Elisabeth / Blons, Hélène. ·INSERM UMR-S1147, Paris Sorbonne Cité Université, Paris, France. · Department of Medical Oncology, Hôpital Européen Georges Pompidou (HEGP), Assistance Publique - Hôpitaux de Paris, Paris, France. · Department of Biochemistry, Pharmacogenetic and Molecular Oncology Unit, Hôpital Européen Georges Pompidou (HEGP), Assistance Publique - Hôpitaux de Paris, Paris, France. · Department of Pathology, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France. · INSERM U1138, Paris Sorbonne Cité Université, Paris, France. · Department of Thoracic Surgery, Hôpital Cochin, Assistance publique Hôpitaux de Paris, Paris, France. · Department of Pathology, Hôpital Européen Georges Pompidou (HEGP), Assistance Publique - Hôpitaux de Paris, Paris, France. · Department of Pathology, Hôpital Bichat, Assistance Publique - Hôpitaux de Paris, Paris, France. · Department of Thoracic Surgery, Hôpital Européen Georges Pompidou (HEGP), Assistance Publique - Hôpitaux de Paris, Paris, France. ·Oncotarget · Pubmed #26625312.

ABSTRACT: STK11 is commonly mutated in lung cancer. In light of recent experimental data showing that specific STK11 mutants could acquire oncogenic activities due to the synthesis of a short STK11 isoform, we investigated whether this new classification of STK11 mutants could help refine its role as a prognostic marker. We conducted a retrospective high-throughput genotyping study in 567 resected non-squamous non-small-cell lung cancer (NSCLC) patients. STK11 exons 1 or 2 mutations (STK11ex1-2) with potential oncogenic activity were analyzed separately from exons 3 to 9 (STK11ex3-9). STK11ex1-2 and STK11ex3-9 mutations occurred in 5% and 14% of NSCLC. STK11 mutated patients were younger (P = .01) and smokers (P< .0001). STK11 mutations were significantly associated with KRAS and inversely with EGFR mutations. After a median follow-up of 7.2 years (95%CI 6.8-.4), patients with STK11ex1-2 mutation had a median OS of 24 months (95%CI 15-57) as compared to 69 months (95%CI 56-93) for wild-type (log-rank, P = .005) and to 91 months (95%CI 57-unreached) for STK11ex3-9 mutations (P = .003). In multivariate analysis, STK11ex1-2 mutations remained associated with a poor prognosis (P = .002). Results were validated in two public datasets. Western blots showed that STK11ex1-2 mutatedtumors expressed short STK11 isoforms. Finally using mRNAseq data from the TCGA cohort, we showed that a stroma-derived poor prognosis signature was enriched in STK11ex1-2 mutated tumors. All together our results show that STK11ex1-2 mutations delineate an aggressive subtype of lung cancer for which a targeted treatment through STK11 inhibition might offer new opportunities.

Next